Compare Eli Lilly And Co (LLY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Novo Nordisk A/S — how do they compare? Eli Lilly And Co trades at $1,221.3 (market cap $1.08T), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Eli Lilly And Co is far larger — about 5.2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| LLY | NVO | |
|---|---|---|
Market Cap | $1.08T | $207.85B |
Sector | Health | Health |
52-Week High | $1.24K | $63.98 |
52-Week Low | $639.43 | $35.29 |
Enterprise Value | $1.13T | $222.55B |
Dividend Yield | 0.57% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
